Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients

The propensity of myelodysplastic syndrome (MDS) to transform into acute myeloid leukemia (AML) suggests the existence of common pathogenic components for these malignancies. Here, four genes implicated in the developmentof AML were examined for promoter CpG island hypermethylation in cells from 37 patients with different stages of MDS. Aberrant methylation was detected by polymerase chain reaction amplification of bisulfite-treated DNA followed by denaturing gradient gel electrophoresis. The highest rate of methylation was found for p15 I N K 4 B (51%), followed by HIC1 (32%), CDH1 (27%), and ER (19%). Concurrent hypermethylation of ≥3 genes was more frequent in advanced compared with early-stage MDS (P ≤ 0.05), and hypermethylation of p15 I N K 4 B was associated with leukemic transformation in early MDS (P < 0.05). The median overall survival was 17 months for cases showing hypermethylation of ≥1 genes vs. 67 months for cases without hypermethylation (P = 0.002). Specifically, promoter hypermethylation identified a subgroup of early MDS with a particularly poor prognosis (median overall survival 20 months vs. 102 months; P = 0.004). In multivariate analysis including stage and thrombocyte count, hypermethylation of ≥1 genes was an independent negative prognostic factor (P < 0.05). These data suggest that hypermethylation of p15 I N K 4 B , HIC1, CDH1, and ER contribute to the development and outcome of MDS.